ER fluid showdown: which IV fluid saves more sepsis patients?
NCT ID NCT07240701
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether Ringer's lactate or normal saline is better for the first fluids given to adults with sepsis in the emergency department. About 88 participants will receive one of the two fluids and be monitored for 24 hours. The main goal is to see if one fluid reduces deaths within that day.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 88 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult male or female patients (≥18 years of age) presenting to the emergency department. * Diagnosed or suspected sepsis secondary to an infectious cause. * Provision of written informed consent by the patient, or if the patient is unable to consent, by a first-degree relative or legally authorized representative. Exclusion Criteria: * Age under 18 years old. * Pregnant women. * Informed consent was not obtained from the patient or their first-degree relative/legal guardian. * Patients who are receiving cardiopulmonary resuscitation (CPR) or who require endotracheal intubation at the time of presentation. * Patients with severe volume depletion unrelated to sepsis (e.g., diabetic ketoacidosis, burns, or active gastrointestinal bleeding). * Patients with severe hyperkalemia (serum potassium level of at least 6.5 mmol/L with ECG changes). * Patients with hypotension that is not related to sepsis (e.g., active hemorrhage or intracranial bleeding). * Patients with clinical signs of pulmonary edema or congestive heart failure. * Cases in which the treating physician determines that one isotonic crystalloid (Ringer's lactate or 0.9% NaCl) is clearly superior to the other due to clinical condition or comorbidities. * Cases in which the treating physician anticipates that fluid therapy might be delayed due to study participation. * Patients requiring immediate hospital or ICU admission before completion of initial emergency department resuscitation. * Patients with sepsis sources requiring urgent invasive intervention known to directly affect mortality (e.g., an undrainable abscess or osteomyelitis). Additional exclusion criteria based on the contraindications listed in the Ringer's lactate product information:, * Known hypersensitivity to sodium lactate. * Extracellular hyperhydration or hypervolemia. * Severe renal failure with oliguria or anuria. * Decompensated heart failure. * Hypercalcemia. * Metabolic alkalosis or severe metabolic acidosis. * Conditions associated with impaired lactate metabolism, such as lactic acidosis, severe liver failure, and cirrhosis with ascites. * Current use of digitalis preparations (e.g., digoxin).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sepsis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Kutahya City Hospital
Kütahya, 43100, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two blood markers catch sepsis before it turns deadly?
- Two cheap blood ratios put to the test as sepsis death predictors
- Can a computer model speed up sepsis blood tests?
- Stem cells put to the test against Sepsis's immune chaos
- Can the immune system reveal who will suffer kidney injury after sepsis?
- A routine calcium reading could reveal how sick a sepsis patient really is